CB-839 etanserin 7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2

7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2

4)5)85-68(93)16-12-9-13-17-69(94)90-42-36-87(37-43-90)35-33-59(49-102-62-14-10-8-11-15-62)84-65-31-30-63(45-67(65)104(98

Fudosteine treatment reduces the expression levels of p-p38 MAPK and p-ERK in vivo and of p-ERK in vitro

It is also alleged to be an aphrodisiac

CB-839 etanserin 7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2Telaglenastat, also known as CB 839, an is orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Telaglenastat selectively and irreversibly inhibits glutaminase. By blocking glutamine utilization, proliferation in rapidly growing cells is impaired. Glutamine dependent tumors rely on the conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the